Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016

  • ID: 3972684
  • Report
  • 320 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • ArQule, Inc.
  • Boston Biomedical, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Imugene Limited
  • Merck & Co., Inc.
  • MORE
Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016

The latest Pharmaceutical and Healthcare disease pipeline guide Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline landscape.

Gastroesophageal (GE) junction adenocarcinomas are carcinomas of the esophagus and the gastro-esophageal junction. Symptoms include dysphasia, weight loss, cough, odynophagia, pain and hoarseness. Risk factors include age, overweight or obese, gastroesophageal reflux disease (GERD), smoking and alcoholism. Treatment includes chemotherapy and radiation therapy.

Report Highlights:

The Pharmaceutical and Healthcare latest pipeline guide Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 8, 23, 10 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.Adenocarcinoma Of The Gastroesophageal Junction.

Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction (Oncology).
- The pipeline guide reviews pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Adenocarcinoma Of The Gastroesophageal Junction (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Adenocarcinoma Of The Gastroesophageal Junction (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction (Oncology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • ArQule, Inc.
  • Boston Biomedical, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Imugene Limited
  • Merck & Co., Inc.
  • MORE
Introduction

Adenocarcinoma Of The Gastroesophageal Junction Overview

Therapeutics Development

Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Overview

Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis

Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Development by Companies

Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Investigation by Universities/Institutes

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Adenocarcinoma Of The Gastroesophageal Junction - Products under Development by Companies

Adenocarcinoma Of The Gastroesophageal Junction - Products under Investigation by Universities/Institutes

Adenocarcinoma Of The Gastroesophageal Junction - Companies Involved in Therapeutics Development

AB Science SA

AbbVie Inc

Advenchen Laboratories, LLC

Amgen Inc.

ArQule, Inc.

AstraZeneca Plc

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Cerulean Pharma, Inc.

Daiichi Sankyo Company, Limited

Dr. Reddy's Laboratories Limited

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Ganymed Pharmaceuticals AG

Genentech Inc

Gilead Sciences, Inc.

Hutchison MediPharma Limited

Imugene Limited

Mebiopharm Co., Ltd.

MedImmune LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

Neopharm Ltd.

Novartis AG

Oncobiologics, Inc.

Panacea Biotec Limited

Sanofi

Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AL-3818 - Drug Profile

alpelisib - Drug Profile

AMG-337 - Drug Profile

atezolizumab - Drug Profile

avelumab - Drug Profile

AZD-4547 - Drug Profile

AZD-6738 - Drug Profile

BI-853520 - Drug Profile

cabazitaxel - Drug Profile

catumaxomab - Drug Profile

Cellular Immunotherapy for Oncology - Drug Profile

ceritinib - Drug Profile

CRLX-101 - Drug Profile

DS-8201 - Drug Profile

durvalumab - Drug Profile

durvalumab + tremelimumab - Drug Profile

emibetuzumab - Drug Profile

GS-5745 - Drug Profile

ibrutinib - Drug Profile

IMAB-362 - Drug Profile

IMU-131 - Drug Profile

ipatasertib - Drug Profile

ipilimumab - Drug Profile

JS-001 - Drug Profile

LAG-525 - Drug Profile

LY-3127804 - Drug Profile

masitinib - Drug Profile

merestinib - Drug Profile

napabucasin - Drug Profile

nimotuzumab - Drug Profile

oxaliplatin - Drug Profile

panitumumab - Drug Profile

PDR-001 - Drug Profile

pembrolizumab - Drug Profile

pertuzumab - Drug Profile

ramucirumab - Drug Profile

SAR-408701 - Drug Profile

savolitinib - Drug Profile

serabelisib - Drug Profile

sonidegib phosphate - Drug Profile

tivantinib - Drug Profile

trastuzumab biosimilar - Drug Profile

trastuzumab biosimilar - Drug Profile

trastuzumab biosimilar - Drug Profile

trastuzumab biosimilar - Drug Profile

trastuzumab biosimilar - Drug Profile

tremelimumab - Drug Profile

Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects

Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products

Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science SA, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AbbVie Inc, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Advenchen Laboratories, LLC, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca Plc, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Daiichi Sankyo Company, Limited, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech Inc, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Hutchison MediPharma Limited, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Imugene Limited, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by MedImmune LLC, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck KGaA, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals Inc, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Neopharm Ltd., H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Novartis AG, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Oncobiologics, Inc., H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Sanofi, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects, H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects (Contd..1), H2 2016

Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016

Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • AbbVie Inc
  • Advenchen Laboratories, LLC
  • Amgen Inc.
  • ArQule, Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Cerulean Pharma, Inc.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Ganymed Pharmaceuticals AG
  • Genentech Inc
  • Gilead Sciences, Inc.
  • Hutchison MediPharma Limited
  • Imugene Limited
  • Mebiopharm Co., Ltd.
  • MedImmune LLC
  • Merck & Co., Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • Neopharm Ltd.
  • Novartis AG
  • Oncobiologics, Inc.
  • Panacea Biotec Limited
  • Sanofi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll